nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Epirubicin—pancreatic cancer	0.205	1	CrCtD
Doxorubicin—Anthracyclines—Epirubicin—pancreatic cancer	0.113	0.402	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Irinotecan—pancreatic cancer	0.109	0.389	CiPCiCtD
Doxorubicin—liver cancer—pancreatic cancer	0.0701	0.435	CtDrD
Doxorubicin—Topoisomerase Inhibitors—Epirubicin—pancreatic cancer	0.0588	0.21	CiPCiCtD
Doxorubicin—stomach cancer—pancreatic cancer	0.051	0.317	CtDrD
Doxorubicin—Valrubicin—Epirubicin—pancreatic cancer	0.0434	0.333	CrCrCtD
Doxorubicin—Idarubicin—Epirubicin—pancreatic cancer	0.0434	0.333	CrCrCtD
Doxorubicin—Daunorubicin—Epirubicin—pancreatic cancer	0.0434	0.333	CrCrCtD
Doxorubicin—kidney cancer—pancreatic cancer	0.0398	0.248	CtDrD
Doxorubicin—DHCR7—Tamoxifen—pancreatic cancer	0.0252	0.173	CbGbCtD
Doxorubicin—AURKA—Epirubicin—pancreatic cancer	0.0199	0.137	CbGbCtD
Doxorubicin—DHCR7—Epirubicin—pancreatic cancer	0.0199	0.137	CbGbCtD
Doxorubicin—YWHAG—Epirubicin—pancreatic cancer	0.0199	0.137	CbGbCtD
Doxorubicin—ABCC10—Gemcitabine—pancreatic cancer	0.00632	0.0436	CbGbCtD
Doxorubicin—ABCC10—Docetaxel—pancreatic cancer	0.00413	0.0285	CbGbCtD
Doxorubicin—TOP2A—Epirubicin—pancreatic cancer	0.00404	0.0278	CbGbCtD
Doxorubicin—ABCB11—Tamoxifen—pancreatic cancer	0.00399	0.0275	CbGbCtD
Doxorubicin—CYP1B1—Tamoxifen—pancreatic cancer	0.00399	0.0275	CbGbCtD
Doxorubicin—ABCC3—Fluorouracil—pancreatic cancer	0.0034	0.0234	CbGbCtD
Doxorubicin—CYP1B1—Erlotinib—pancreatic cancer	0.00339	0.0234	CbGbCtD
Doxorubicin—CYP1B1—Docetaxel—pancreatic cancer	0.00225	0.0155	CbGbCtD
Doxorubicin—ABCC1—Epirubicin—pancreatic cancer	0.00224	0.0154	CbGbCtD
Doxorubicin—ABCC1—Irinotecan—pancreatic cancer	0.00218	0.015	CbGbCtD
Doxorubicin—ABCC2—Tamoxifen—pancreatic cancer	0.0021	0.0145	CbGbCtD
Doxorubicin—ABCG2—Tamoxifen—pancreatic cancer	0.0019	0.0131	CbGbCtD
Doxorubicin—ABCG2—Erlotinib—pancreatic cancer	0.00161	0.0111	CbGbCtD
Doxorubicin—ABCB11—bile duct—pancreatic cancer	0.00161	0.121	CbGeAlD
Doxorubicin—ABCC2—Irinotecan—pancreatic cancer	0.00161	0.0111	CbGbCtD
Doxorubicin—ABCC1—Docetaxel—pancreatic cancer	0.00159	0.011	CbGbCtD
Doxorubicin—ABCG2—Irinotecan—pancreatic cancer	0.00146	0.01	CbGbCtD
Doxorubicin—ABCG2—Fluorouracil—pancreatic cancer	0.0014	0.00963	CbGbCtD
Doxorubicin—CYP2B6—Tamoxifen—pancreatic cancer	0.00133	0.00919	CbGbCtD
Doxorubicin—ABCB11—bile—pancreatic cancer	0.00124	0.0931	CbGeAlD
Doxorubicin—ABCC2—Docetaxel—pancreatic cancer	0.00118	0.00814	CbGbCtD
Doxorubicin—ABCC2—Sunitinib—pancreatic cancer	0.00118	0.0081	CbGbCtD
Doxorubicin—ABCG2—Docetaxel—pancreatic cancer	0.00107	0.00736	CbGbCtD
Doxorubicin—ABCG2—Sunitinib—pancreatic cancer	0.00106	0.00732	CbGbCtD
Doxorubicin—ABCC3—bile duct—pancreatic cancer	0.00103	0.0771	CbGeAlD
Doxorubicin—CYP2B6—Irinotecan—pancreatic cancer	0.00102	0.00706	CbGbCtD
Doxorubicin—ABCC2—bile duct—pancreatic cancer	0.00082	0.0616	CbGeAlD
Doxorubicin—NOS3—umbilical vein—pancreatic cancer	0.00078	0.0586	CbGeAlD
Doxorubicin—ABCB1—Tamoxifen—pancreatic cancer	0.000684	0.00471	CbGbCtD
Doxorubicin—CYP2D6—Tamoxifen—pancreatic cancer	0.000644	0.00444	CbGbCtD
Doxorubicin—ABCC2—bile—pancreatic cancer	0.00063	0.0474	CbGeAlD
Doxorubicin—ABCB1—Gemcitabine—pancreatic cancer	0.000589	0.00406	CbGbCtD
Doxorubicin—ABCB1—Erlotinib—pancreatic cancer	0.000582	0.00401	CbGbCtD
Doxorubicin—CYP2D6—Erlotinib—pancreatic cancer	0.000548	0.00378	CbGbCtD
Doxorubicin—ABCB1—Irinotecan—pancreatic cancer	0.000525	0.00362	CbGbCtD
Doxorubicin—CYP3A4—Tamoxifen—pancreatic cancer	0.00041	0.00282	CbGbCtD
Doxorubicin—ABCB1—Docetaxel—pancreatic cancer	0.000385	0.00265	CbGbCtD
Doxorubicin—ABCB1—Sunitinib—pancreatic cancer	0.000383	0.00264	CbGbCtD
Doxorubicin—AKR1A1—islet of Langerhans—pancreatic cancer	0.000365	0.0274	CbGeAlD
Doxorubicin—CYP3A4—Erlotinib—pancreatic cancer	0.000348	0.0024	CbGbCtD
Doxorubicin—NDUFS7—islet of Langerhans—pancreatic cancer	0.000332	0.0249	CbGeAlD
Doxorubicin—CYP3A4—Irinotecan—pancreatic cancer	0.000315	0.00217	CbGbCtD
Doxorubicin—NDUFS2—islet of Langerhans—pancreatic cancer	0.000275	0.0207	CbGeAlD
Doxorubicin—NDUFS3—islet of Langerhans—pancreatic cancer	0.000272	0.0204	CbGeAlD
Doxorubicin—DHCR7—islet of Langerhans—pancreatic cancer	0.000258	0.0194	CbGeAlD
Doxorubicin—AKR1A1—pancreas—pancreatic cancer	0.000257	0.0193	CbGeAlD
Doxorubicin—NQO1—gall bladder—pancreatic cancer	0.000244	0.0183	CbGeAlD
Doxorubicin—YWHAG—islet of Langerhans—pancreatic cancer	0.000237	0.0178	CbGeAlD
Doxorubicin—CYP3A4—Docetaxel—pancreatic cancer	0.000231	0.00159	CbGbCtD
Doxorubicin—CYP3A4—Sunitinib—pancreatic cancer	0.00023	0.00158	CbGbCtD
Doxorubicin—AKR1A1—digestive system—pancreatic cancer	0.000219	0.0165	CbGeAlD
Doxorubicin—ABCC3—gall bladder—pancreatic cancer	0.000219	0.0165	CbGeAlD
Doxorubicin—RALBP1—islet of Langerhans—pancreatic cancer	0.000214	0.0161	CbGeAlD
Doxorubicin—CBR1—islet of Langerhans—pancreatic cancer	0.0002	0.015	CbGeAlD
Doxorubicin—NDUFS7—digestive system—pancreatic cancer	0.000199	0.015	CbGeAlD
Doxorubicin—AKR1C3—islet of Langerhans—pancreatic cancer	0.000197	0.0148	CbGeAlD
Doxorubicin—NDUFS2—pancreas—pancreatic cancer	0.000193	0.0145	CbGeAlD
Doxorubicin—NDUFS3—pancreas—pancreatic cancer	0.000191	0.0143	CbGeAlD
Doxorubicin—AURKA—digestive system—pancreatic cancer	0.000185	0.0139	CbGeAlD
Doxorubicin—DHCR7—pancreas—pancreatic cancer	0.000181	0.0136	CbGeAlD
Doxorubicin—POR—islet of Langerhans—pancreatic cancer	0.00018	0.0135	CbGeAlD
Doxorubicin—YWHAG—pancreas—pancreatic cancer	0.000166	0.0125	CbGeAlD
Doxorubicin—NOS1—digestive system—pancreatic cancer	0.000166	0.0125	CbGeAlD
Doxorubicin—NDUFS2—digestive system—pancreatic cancer	0.000165	0.0124	CbGeAlD
Doxorubicin—NDUFS3—digestive system—pancreatic cancer	0.000163	0.0123	CbGeAlD
Doxorubicin—NQO1—islet of Langerhans—pancreatic cancer	0.00016	0.012	CbGeAlD
Doxorubicin—DHCR7—digestive system—pancreatic cancer	0.000155	0.0116	CbGeAlD
Doxorubicin—RALBP1—pancreas—pancreatic cancer	0.00015	0.0113	CbGeAlD
Doxorubicin—AURKA—Topotecan—Irinotecan—pancreatic cancer	0.000149	0.224	CbGdCrCtD
Doxorubicin—YWHAG—digestive system—pancreatic cancer	0.000142	0.0107	CbGeAlD
Doxorubicin—XDH—digestive system—pancreatic cancer	0.000139	0.0104	CbGeAlD
Doxorubicin—AKR1C3—pancreas—pancreatic cancer	0.000139	0.0104	CbGeAlD
Doxorubicin—ABCB11—digestive system—pancreatic cancer	0.000135	0.0102	CbGeAlD
Doxorubicin—RALBP1—digestive system—pancreatic cancer	0.000128	0.00964	CbGeAlD
Doxorubicin—NOS3—digestive system—pancreatic cancer	0.000126	0.00949	CbGeAlD
Doxorubicin—CBR1—digestive system—pancreatic cancer	0.00012	0.009	CbGeAlD
Doxorubicin—NQO1—pancreas—pancreatic cancer	0.000112	0.00845	CbGeAlD
Doxorubicin—NQO1—digestive system—pancreatic cancer	9.6e-05	0.00721	CbGeAlD
Doxorubicin—ABCC3—digestive system—pancreatic cancer	8.62e-05	0.00647	CbGeAlD
Doxorubicin—ABCC10—digestive system—pancreatic cancer	8.57e-05	0.00644	CbGeAlD
Doxorubicin—ABCC2—digestive system—pancreatic cancer	6.88e-05	0.00517	CbGeAlD
Doxorubicin—CYP1B1—digestive system—pancreatic cancer	6.74e-05	0.00507	CbGeAlD
Doxorubicin—CBR3—Daunorubicin—Epirubicin—pancreatic cancer	6.63e-05	0.0998	CbGdCrCtD
Doxorubicin—CBR3—Idarubicin—Epirubicin—pancreatic cancer	6.63e-05	0.0998	CbGdCrCtD
Doxorubicin—TOP2A—Topotecan—Irinotecan—pancreatic cancer	5.68e-05	0.0855	CbGdCrCtD
Doxorubicin—CBR3—Azacitidine—Gemcitabine—pancreatic cancer	5.13e-05	0.0772	CbGdCrCtD
Doxorubicin—CYP2B6—digestive system—pancreatic cancer	4.63e-05	0.00348	CbGeAlD
Doxorubicin—ABCB1—islet of Langerhans—pancreatic cancer	4.12e-05	0.0031	CbGeAlD
Doxorubicin—TOP2A—Paclitaxel—Docetaxel—pancreatic cancer	3.99e-05	0.06	CbGdCrCtD
Doxorubicin—TOP2A—Gefitinib—Erlotinib—pancreatic cancer	3.82e-05	0.0576	CbGdCrCtD
Doxorubicin—CBR1—Azacitidine—Gemcitabine—pancreatic cancer	3.8e-05	0.0572	CbGdCrCtD
Doxorubicin—AURKA—Cytarabine—Gemcitabine—pancreatic cancer	3.77e-05	0.0567	CbGdCrCtD
Doxorubicin—CYP3A4—digestive system—pancreatic cancer	3.5e-05	0.00263	CbGeAlD
Doxorubicin—AURKA—Idarubicin—Epirubicin—pancreatic cancer	3.49e-05	0.0526	CbGdCrCtD
Doxorubicin—AURKA—Daunorubicin—Epirubicin—pancreatic cancer	3.49e-05	0.0526	CbGdCrCtD
Doxorubicin—CYP2D6—digestive system—pancreatic cancer	3.44e-05	0.00259	CbGeAlD
Doxorubicin—ABCB1—pancreas—pancreatic cancer	2.9e-05	0.00218	CbGeAlD
Doxorubicin—ABCB1—digestive system—pancreatic cancer	2.48e-05	0.00186	CbGeAlD
Doxorubicin—TOP2A—Cytarabine—Gemcitabine—pancreatic cancer	1.44e-05	0.0217	CbGdCrCtD
Doxorubicin—TOP2A—Daunorubicin—Epirubicin—pancreatic cancer	1.34e-05	0.0201	CbGdCrCtD
Doxorubicin—TOP2A—Idarubicin—Epirubicin—pancreatic cancer	1.34e-05	0.0201	CbGdCrCtD
Doxorubicin—TOP2A—Azacitidine—Gemcitabine—pancreatic cancer	1.03e-05	0.0155	CbGdCrCtD
Doxorubicin—Somnolence—Gemcitabine—pancreatic cancer	7.77e-06	0.000175	CcSEcCtD
Doxorubicin—Hypokalaemia—Epirubicin—pancreatic cancer	7.74e-06	0.000175	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	7.74e-06	0.000175	CcSEcCtD
Doxorubicin—Fatigue—Irinotecan—pancreatic cancer	7.73e-06	0.000175	CcSEcCtD
Doxorubicin—Paraesthesia—Fluorouracil—pancreatic cancer	7.71e-06	0.000174	CcSEcCtD
Doxorubicin—Alopecia—Docetaxel—pancreatic cancer	7.71e-06	0.000174	CcSEcCtD
Doxorubicin—Pruritus—Sunitinib—pancreatic cancer	7.7e-06	0.000174	CcSEcCtD
Doxorubicin—Breast disorder—Epirubicin—pancreatic cancer	7.69e-06	0.000174	CcSEcCtD
Doxorubicin—Pain—Irinotecan—pancreatic cancer	7.67e-06	0.000173	CcSEcCtD
Doxorubicin—Constipation—Irinotecan—pancreatic cancer	7.67e-06	0.000173	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	7.66e-06	0.000173	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	7.66e-06	0.000173	CcSEcCtD
Doxorubicin—Dyspnoea—Fluorouracil—pancreatic cancer	7.66e-06	0.000173	CcSEcCtD
Doxorubicin—Mental disorder—Docetaxel—pancreatic cancer	7.64e-06	0.000173	CcSEcCtD
Doxorubicin—Somnolence—Fluorouracil—pancreatic cancer	7.64e-06	0.000172	CcSEcCtD
Doxorubicin—Nasopharyngitis—Epirubicin—pancreatic cancer	7.61e-06	0.000172	CcSEcCtD
Doxorubicin—Erythema—Docetaxel—pancreatic cancer	7.6e-06	0.000172	CcSEcCtD
Doxorubicin—Malnutrition—Docetaxel—pancreatic cancer	7.6e-06	0.000172	CcSEcCtD
Doxorubicin—Decreased appetite—Gemcitabine—pancreatic cancer	7.59e-06	0.000172	CcSEcCtD
Doxorubicin—Dyspepsia—Fluorouracil—pancreatic cancer	7.56e-06	0.000171	CcSEcCtD
Doxorubicin—Nausea—Tamoxifen—pancreatic cancer	7.55e-06	0.000171	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	7.54e-06	0.00017	CcSEcCtD
Doxorubicin—Fatigue—Gemcitabine—pancreatic cancer	7.53e-06	0.00017	CcSEcCtD
Doxorubicin—Gastritis—Epirubicin—pancreatic cancer	7.53e-06	0.00017	CcSEcCtD
Doxorubicin—Muscular weakness—Epirubicin—pancreatic cancer	7.5e-06	0.000169	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	7.5e-06	0.000169	CcSEcCtD
Doxorubicin—Pain—Gemcitabine—pancreatic cancer	7.47e-06	0.000169	CcSEcCtD
Doxorubicin—Constipation—Gemcitabine—pancreatic cancer	7.47e-06	0.000169	CcSEcCtD
Doxorubicin—Nausea—Erlotinib—pancreatic cancer	7.47e-06	0.000169	CcSEcCtD
Doxorubicin—Decreased appetite—Fluorouracil—pancreatic cancer	7.47e-06	0.000169	CcSEcCtD
Doxorubicin—Diarrhoea—Sunitinib—pancreatic cancer	7.45e-06	0.000168	CcSEcCtD
Doxorubicin—Dysgeusia—Docetaxel—pancreatic cancer	7.44e-06	0.000168	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	7.42e-06	0.000167	CcSEcCtD
Doxorubicin—Abdominal distension—Epirubicin—pancreatic cancer	7.4e-06	0.000167	CcSEcCtD
Doxorubicin—Feeling abnormal—Irinotecan—pancreatic cancer	7.39e-06	0.000167	CcSEcCtD
Doxorubicin—Dysphagia—Epirubicin—pancreatic cancer	7.35e-06	0.000166	CcSEcCtD
Doxorubicin—Asthma—Epirubicin—pancreatic cancer	7.35e-06	0.000166	CcSEcCtD
Doxorubicin—Influenza—Epirubicin—pancreatic cancer	7.35e-06	0.000166	CcSEcCtD
Doxorubicin—Back pain—Docetaxel—pancreatic cancer	7.35e-06	0.000166	CcSEcCtD
Doxorubicin—Pain—Fluorouracil—pancreatic cancer	7.35e-06	0.000166	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Irinotecan—pancreatic cancer	7.33e-06	0.000166	CcSEcCtD
Doxorubicin—Muscle spasms—Docetaxel—pancreatic cancer	7.3e-06	0.000165	CcSEcCtD
Doxorubicin—Eosinophilia—Epirubicin—pancreatic cancer	7.28e-06	0.000164	CcSEcCtD
Doxorubicin—Pancreatitis—Epirubicin—pancreatic cancer	7.21e-06	0.000163	CcSEcCtD
Doxorubicin—Dizziness—Sunitinib—pancreatic cancer	7.2e-06	0.000163	CcSEcCtD
Doxorubicin—Feeling abnormal—Gemcitabine—pancreatic cancer	7.2e-06	0.000163	CcSEcCtD
Doxorubicin—Angina pectoris—Epirubicin—pancreatic cancer	7.16e-06	0.000162	CcSEcCtD
Doxorubicin—Abdominal pain—Irinotecan—pancreatic cancer	7.09e-06	0.00016	CcSEcCtD
Doxorubicin—Body temperature increased—Irinotecan—pancreatic cancer	7.09e-06	0.00016	CcSEcCtD
Doxorubicin—Feeling abnormal—Fluorouracil—pancreatic cancer	7.08e-06	0.00016	CcSEcCtD
Doxorubicin—Bronchitis—Epirubicin—pancreatic cancer	7.07e-06	0.00016	CcSEcCtD
Doxorubicin—Anaemia—Docetaxel—pancreatic cancer	7.02e-06	0.000159	CcSEcCtD
Doxorubicin—Pancytopenia—Epirubicin—pancreatic cancer	6.98e-06	0.000158	CcSEcCtD
Doxorubicin—Vomiting—Sunitinib—pancreatic cancer	6.92e-06	0.000156	CcSEcCtD
Doxorubicin—Body temperature increased—Gemcitabine—pancreatic cancer	6.91e-06	0.000156	CcSEcCtD
Doxorubicin—Dysuria—Epirubicin—pancreatic cancer	6.88e-06	0.000155	CcSEcCtD
Doxorubicin—Neutropenia—Epirubicin—pancreatic cancer	6.88e-06	0.000155	CcSEcCtD
Doxorubicin—Rash—Sunitinib—pancreatic cancer	6.86e-06	0.000155	CcSEcCtD
Doxorubicin—Dermatitis—Sunitinib—pancreatic cancer	6.86e-06	0.000155	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Epirubicin—pancreatic cancer	6.83e-06	0.000154	CcSEcCtD
Doxorubicin—Urticaria—Fluorouracil—pancreatic cancer	6.82e-06	0.000154	CcSEcCtD
Doxorubicin—Headache—Sunitinib—pancreatic cancer	6.82e-06	0.000154	CcSEcCtD
Doxorubicin—Syncope—Docetaxel—pancreatic cancer	6.81e-06	0.000154	CcSEcCtD
Doxorubicin—Leukopenia—Docetaxel—pancreatic cancer	6.8e-06	0.000154	CcSEcCtD
Doxorubicin—Pollakiuria—Epirubicin—pancreatic cancer	6.79e-06	0.000153	CcSEcCtD
Doxorubicin—Body temperature increased—Fluorouracil—pancreatic cancer	6.79e-06	0.000153	CcSEcCtD
Doxorubicin—Palpitations—Docetaxel—pancreatic cancer	6.71e-06	0.000152	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Epirubicin—pancreatic cancer	6.71e-06	0.000152	CcSEcCtD
Doxorubicin—Weight increased—Epirubicin—pancreatic cancer	6.69e-06	0.000151	CcSEcCtD
Doxorubicin—Loss of consciousness—Docetaxel—pancreatic cancer	6.68e-06	0.000151	CcSEcCtD
Doxorubicin—Weight decreased—Epirubicin—pancreatic cancer	6.65e-06	0.00015	CcSEcCtD
Doxorubicin—Hyperglycaemia—Epirubicin—pancreatic cancer	6.63e-06	0.00015	CcSEcCtD
Doxorubicin—Cough—Docetaxel—pancreatic cancer	6.63e-06	0.00015	CcSEcCtD
Doxorubicin—Hypersensitivity—Irinotecan—pancreatic cancer	6.61e-06	0.000149	CcSEcCtD
Doxorubicin—Pneumonia—Epirubicin—pancreatic cancer	6.59e-06	0.000149	CcSEcCtD
Doxorubicin—Convulsion—Docetaxel—pancreatic cancer	6.58e-06	0.000149	CcSEcCtD
Doxorubicin—Hypertension—Docetaxel—pancreatic cancer	6.56e-06	0.000148	CcSEcCtD
Doxorubicin—Infestation NOS—Epirubicin—pancreatic cancer	6.56e-06	0.000148	CcSEcCtD
Doxorubicin—Drowsiness—Epirubicin—pancreatic cancer	6.56e-06	0.000148	CcSEcCtD
Doxorubicin—Infestation—Epirubicin—pancreatic cancer	6.56e-06	0.000148	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	6.5e-06	0.000147	CcSEcCtD
Doxorubicin—Arthralgia—Docetaxel—pancreatic cancer	6.47e-06	0.000146	CcSEcCtD
Doxorubicin—Myalgia—Docetaxel—pancreatic cancer	6.47e-06	0.000146	CcSEcCtD
Doxorubicin—Chest pain—Docetaxel—pancreatic cancer	6.47e-06	0.000146	CcSEcCtD
Doxorubicin—Nausea—Sunitinib—pancreatic cancer	6.47e-06	0.000146	CcSEcCtD
Doxorubicin—Renal failure—Epirubicin—pancreatic cancer	6.44e-06	0.000146	CcSEcCtD
Doxorubicin—Asthenia—Irinotecan—pancreatic cancer	6.43e-06	0.000145	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Epirubicin—pancreatic cancer	6.43e-06	0.000145	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	6.42e-06	0.000145	CcSEcCtD
Doxorubicin—Stomatitis—Epirubicin—pancreatic cancer	6.39e-06	0.000144	CcSEcCtD
Doxorubicin—Jaundice—Epirubicin—pancreatic cancer	6.39e-06	0.000144	CcSEcCtD
Doxorubicin—Urinary tract infection—Epirubicin—pancreatic cancer	6.37e-06	0.000144	CcSEcCtD
Doxorubicin—Conjunctivitis—Epirubicin—pancreatic cancer	6.37e-06	0.000144	CcSEcCtD
Doxorubicin—Hypersensitivity—Fluorouracil—pancreatic cancer	6.33e-06	0.000143	CcSEcCtD
Doxorubicin—Dry mouth—Docetaxel—pancreatic cancer	6.32e-06	0.000143	CcSEcCtD
Doxorubicin—Sweating—Epirubicin—pancreatic cancer	6.29e-06	0.000142	CcSEcCtD
Doxorubicin—Asthenia—Gemcitabine—pancreatic cancer	6.27e-06	0.000142	CcSEcCtD
Doxorubicin—Haematuria—Epirubicin—pancreatic cancer	6.25e-06	0.000141	CcSEcCtD
Doxorubicin—Confusional state—Docetaxel—pancreatic cancer	6.25e-06	0.000141	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Epirubicin—pancreatic cancer	6.2e-06	0.00014	CcSEcCtD
Doxorubicin—Oedema—Docetaxel—pancreatic cancer	6.2e-06	0.00014	CcSEcCtD
Doxorubicin—Anaphylactic shock—Docetaxel—pancreatic cancer	6.2e-06	0.00014	CcSEcCtD
Doxorubicin—Epistaxis—Epirubicin—pancreatic cancer	6.18e-06	0.00014	CcSEcCtD
Doxorubicin—Pruritus—Gemcitabine—pancreatic cancer	6.18e-06	0.00014	CcSEcCtD
Doxorubicin—Infection—Docetaxel—pancreatic cancer	6.16e-06	0.000139	CcSEcCtD
Doxorubicin—Sinusitis—Epirubicin—pancreatic cancer	6.15e-06	0.000139	CcSEcCtD
Doxorubicin—Diarrhoea—Irinotecan—pancreatic cancer	6.14e-06	0.000139	CcSEcCtD
Doxorubicin—Agranulocytosis—Epirubicin—pancreatic cancer	6.12e-06	0.000138	CcSEcCtD
Doxorubicin—Shock—Docetaxel—pancreatic cancer	6.1e-06	0.000138	CcSEcCtD
Doxorubicin—Nervous system disorder—Docetaxel—pancreatic cancer	6.08e-06	0.000137	CcSEcCtD
Doxorubicin—Pruritus—Fluorouracil—pancreatic cancer	6.08e-06	0.000137	CcSEcCtD
Doxorubicin—Thrombocytopenia—Docetaxel—pancreatic cancer	6.07e-06	0.000137	CcSEcCtD
Doxorubicin—Tachycardia—Docetaxel—pancreatic cancer	6.05e-06	0.000137	CcSEcCtD
Doxorubicin—Skin disorder—Docetaxel—pancreatic cancer	6.02e-06	0.000136	CcSEcCtD
Doxorubicin—Bradycardia—Epirubicin—pancreatic cancer	5.99e-06	0.000135	CcSEcCtD
Doxorubicin—Diarrhoea—Gemcitabine—pancreatic cancer	5.98e-06	0.000135	CcSEcCtD
Doxorubicin—Dizziness—Irinotecan—pancreatic cancer	5.93e-06	0.000134	CcSEcCtD
Doxorubicin—Haemoglobin—Epirubicin—pancreatic cancer	5.92e-06	0.000134	CcSEcCtD
Doxorubicin—Anorexia—Docetaxel—pancreatic cancer	5.91e-06	0.000133	CcSEcCtD
Doxorubicin—Rhinitis—Epirubicin—pancreatic cancer	5.9e-06	0.000133	CcSEcCtD
Doxorubicin—Hepatitis—Epirubicin—pancreatic cancer	5.89e-06	0.000133	CcSEcCtD
Doxorubicin—Haemorrhage—Epirubicin—pancreatic cancer	5.89e-06	0.000133	CcSEcCtD
Doxorubicin—Diarrhoea—Fluorouracil—pancreatic cancer	5.88e-06	0.000133	CcSEcCtD
Doxorubicin—Hypoaesthesia—Epirubicin—pancreatic cancer	5.86e-06	0.000132	CcSEcCtD
Doxorubicin—Pharyngitis—Epirubicin—pancreatic cancer	5.84e-06	0.000132	CcSEcCtD
Doxorubicin—Urinary tract disorder—Epirubicin—pancreatic cancer	5.81e-06	0.000131	CcSEcCtD
Doxorubicin—Oedema peripheral—Epirubicin—pancreatic cancer	5.8e-06	0.000131	CcSEcCtD
Doxorubicin—Hypotension—Docetaxel—pancreatic cancer	5.79e-06	0.000131	CcSEcCtD
Doxorubicin—Connective tissue disorder—Epirubicin—pancreatic cancer	5.78e-06	0.000131	CcSEcCtD
Doxorubicin—Urethral disorder—Epirubicin—pancreatic cancer	5.77e-06	0.00013	CcSEcCtD
Doxorubicin—Vomiting—Irinotecan—pancreatic cancer	5.7e-06	0.000129	CcSEcCtD
Doxorubicin—Dizziness—Fluorouracil—pancreatic cancer	5.68e-06	0.000128	CcSEcCtD
Doxorubicin—Visual impairment—Epirubicin—pancreatic cancer	5.67e-06	0.000128	CcSEcCtD
Doxorubicin—Rash—Irinotecan—pancreatic cancer	5.65e-06	0.000128	CcSEcCtD
Doxorubicin—Dermatitis—Irinotecan—pancreatic cancer	5.65e-06	0.000128	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.65e-06	0.000128	CcSEcCtD
Doxorubicin—Headache—Irinotecan—pancreatic cancer	5.62e-06	0.000127	CcSEcCtD
Doxorubicin—Insomnia—Docetaxel—pancreatic cancer	5.61e-06	0.000127	CcSEcCtD
Doxorubicin—Paraesthesia—Docetaxel—pancreatic cancer	5.57e-06	0.000126	CcSEcCtD
Doxorubicin—Erythema multiforme—Epirubicin—pancreatic cancer	5.56e-06	0.000126	CcSEcCtD
Doxorubicin—Vomiting—Gemcitabine—pancreatic cancer	5.55e-06	0.000125	CcSEcCtD
Doxorubicin—Dyspnoea—Docetaxel—pancreatic cancer	5.53e-06	0.000125	CcSEcCtD
Doxorubicin—Somnolence—Docetaxel—pancreatic cancer	5.51e-06	0.000124	CcSEcCtD
Doxorubicin—Rash—Gemcitabine—pancreatic cancer	5.51e-06	0.000124	CcSEcCtD
Doxorubicin—Dermatitis—Gemcitabine—pancreatic cancer	5.5e-06	0.000124	CcSEcCtD
Doxorubicin—Eye disorder—Epirubicin—pancreatic cancer	5.5e-06	0.000124	CcSEcCtD
Doxorubicin—Tinnitus—Epirubicin—pancreatic cancer	5.49e-06	0.000124	CcSEcCtD
Doxorubicin—Headache—Gemcitabine—pancreatic cancer	5.47e-06	0.000124	CcSEcCtD
Doxorubicin—Flushing—Epirubicin—pancreatic cancer	5.46e-06	0.000123	CcSEcCtD
Doxorubicin—Cardiac disorder—Epirubicin—pancreatic cancer	5.46e-06	0.000123	CcSEcCtD
Doxorubicin—Vomiting—Fluorouracil—pancreatic cancer	5.46e-06	0.000123	CcSEcCtD
Doxorubicin—Dyspepsia—Docetaxel—pancreatic cancer	5.46e-06	0.000123	CcSEcCtD
Doxorubicin—Rash—Fluorouracil—pancreatic cancer	5.42e-06	0.000122	CcSEcCtD
Doxorubicin—Dermatitis—Fluorouracil—pancreatic cancer	5.41e-06	0.000122	CcSEcCtD
Doxorubicin—Decreased appetite—Docetaxel—pancreatic cancer	5.39e-06	0.000122	CcSEcCtD
Doxorubicin—Headache—Fluorouracil—pancreatic cancer	5.38e-06	0.000122	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.35e-06	0.000121	CcSEcCtD
Doxorubicin—Fatigue—Docetaxel—pancreatic cancer	5.34e-06	0.000121	CcSEcCtD
Doxorubicin—Angiopathy—Epirubicin—pancreatic cancer	5.34e-06	0.000121	CcSEcCtD
Doxorubicin—Nausea—Irinotecan—pancreatic cancer	5.33e-06	0.00012	CcSEcCtD
Doxorubicin—Immune system disorder—Epirubicin—pancreatic cancer	5.32e-06	0.00012	CcSEcCtD
Doxorubicin—Mediastinal disorder—Epirubicin—pancreatic cancer	5.3e-06	0.00012	CcSEcCtD
Doxorubicin—Constipation—Docetaxel—pancreatic cancer	5.3e-06	0.00012	CcSEcCtD
Doxorubicin—Pain—Docetaxel—pancreatic cancer	5.3e-06	0.00012	CcSEcCtD
Doxorubicin—Chills—Epirubicin—pancreatic cancer	5.28e-06	0.000119	CcSEcCtD
Doxorubicin—Arrhythmia—Epirubicin—pancreatic cancer	5.26e-06	0.000119	CcSEcCtD
Doxorubicin—Alopecia—Epirubicin—pancreatic cancer	5.2e-06	0.000117	CcSEcCtD
Doxorubicin—Nausea—Gemcitabine—pancreatic cancer	5.19e-06	0.000117	CcSEcCtD
Doxorubicin—Mental disorder—Epirubicin—pancreatic cancer	5.16e-06	0.000116	CcSEcCtD
Doxorubicin—Malnutrition—Epirubicin—pancreatic cancer	5.12e-06	0.000116	CcSEcCtD
Doxorubicin—Erythema—Epirubicin—pancreatic cancer	5.12e-06	0.000116	CcSEcCtD
Doxorubicin—Feeling abnormal—Docetaxel—pancreatic cancer	5.11e-06	0.000115	CcSEcCtD
Doxorubicin—Nausea—Fluorouracil—pancreatic cancer	5.1e-06	0.000115	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.07e-06	0.000114	CcSEcCtD
Doxorubicin—Flatulence—Epirubicin—pancreatic cancer	5.05e-06	0.000114	CcSEcCtD
Doxorubicin—Tension—Epirubicin—pancreatic cancer	5.03e-06	0.000114	CcSEcCtD
Doxorubicin—Dysgeusia—Epirubicin—pancreatic cancer	5.02e-06	0.000113	CcSEcCtD
Doxorubicin—Nervousness—Epirubicin—pancreatic cancer	4.98e-06	0.000112	CcSEcCtD
Doxorubicin—Back pain—Epirubicin—pancreatic cancer	4.96e-06	0.000112	CcSEcCtD
Doxorubicin—Muscle spasms—Epirubicin—pancreatic cancer	4.93e-06	0.000111	CcSEcCtD
Doxorubicin—Abdominal pain—Docetaxel—pancreatic cancer	4.9e-06	0.000111	CcSEcCtD
Doxorubicin—Body temperature increased—Docetaxel—pancreatic cancer	4.9e-06	0.000111	CcSEcCtD
Doxorubicin—Vision blurred—Epirubicin—pancreatic cancer	4.83e-06	0.000109	CcSEcCtD
Doxorubicin—Ill-defined disorder—Epirubicin—pancreatic cancer	4.75e-06	0.000107	CcSEcCtD
Doxorubicin—Anaemia—Epirubicin—pancreatic cancer	4.74e-06	0.000107	CcSEcCtD
Doxorubicin—Agitation—Epirubicin—pancreatic cancer	4.71e-06	0.000106	CcSEcCtD
Doxorubicin—Malaise—Epirubicin—pancreatic cancer	4.62e-06	0.000104	CcSEcCtD
Doxorubicin—Vertigo—Epirubicin—pancreatic cancer	4.6e-06	0.000104	CcSEcCtD
Doxorubicin—Syncope—Epirubicin—pancreatic cancer	4.59e-06	0.000104	CcSEcCtD
Doxorubicin—Leukopenia—Epirubicin—pancreatic cancer	4.59e-06	0.000104	CcSEcCtD
Doxorubicin—Hypersensitivity—Docetaxel—pancreatic cancer	4.57e-06	0.000103	CcSEcCtD
Doxorubicin—Palpitations—Epirubicin—pancreatic cancer	4.53e-06	0.000102	CcSEcCtD
Doxorubicin—Loss of consciousness—Epirubicin—pancreatic cancer	4.5e-06	0.000102	CcSEcCtD
Doxorubicin—Cough—Epirubicin—pancreatic cancer	4.47e-06	0.000101	CcSEcCtD
Doxorubicin—Asthenia—Docetaxel—pancreatic cancer	4.45e-06	0.0001	CcSEcCtD
Doxorubicin—Convulsion—Epirubicin—pancreatic cancer	4.44e-06	0.0001	CcSEcCtD
Doxorubicin—Hypertension—Epirubicin—pancreatic cancer	4.42e-06	9.99e-05	CcSEcCtD
Doxorubicin—Pruritus—Docetaxel—pancreatic cancer	4.39e-06	9.91e-05	CcSEcCtD
Doxorubicin—Arthralgia—Epirubicin—pancreatic cancer	4.36e-06	9.85e-05	CcSEcCtD
Doxorubicin—Chest pain—Epirubicin—pancreatic cancer	4.36e-06	9.85e-05	CcSEcCtD
Doxorubicin—Myalgia—Epirubicin—pancreatic cancer	4.36e-06	9.85e-05	CcSEcCtD
Doxorubicin—Anxiety—Epirubicin—pancreatic cancer	4.35e-06	9.82e-05	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.33e-06	9.78e-05	CcSEcCtD
Doxorubicin—Discomfort—Epirubicin—pancreatic cancer	4.31e-06	9.73e-05	CcSEcCtD
Doxorubicin—Dry mouth—Epirubicin—pancreatic cancer	4.27e-06	9.63e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Docetaxel—pancreatic cancer	4.24e-06	9.58e-05	CcSEcCtD
Doxorubicin—Confusional state—Epirubicin—pancreatic cancer	4.22e-06	9.52e-05	CcSEcCtD
Doxorubicin—Oedema—Epirubicin—pancreatic cancer	4.18e-06	9.44e-05	CcSEcCtD
Doxorubicin—Anaphylactic shock—Epirubicin—pancreatic cancer	4.18e-06	9.44e-05	CcSEcCtD
Doxorubicin—Infection—Epirubicin—pancreatic cancer	4.15e-06	9.38e-05	CcSEcCtD
Doxorubicin—Shock—Epirubicin—pancreatic cancer	4.11e-06	9.29e-05	CcSEcCtD
Doxorubicin—Nervous system disorder—Epirubicin—pancreatic cancer	4.1e-06	9.26e-05	CcSEcCtD
Doxorubicin—Dizziness—Docetaxel—pancreatic cancer	4.1e-06	9.26e-05	CcSEcCtD
Doxorubicin—Thrombocytopenia—Epirubicin—pancreatic cancer	4.09e-06	9.25e-05	CcSEcCtD
Doxorubicin—Tachycardia—Epirubicin—pancreatic cancer	4.08e-06	9.22e-05	CcSEcCtD
Doxorubicin—Skin disorder—Epirubicin—pancreatic cancer	4.06e-06	9.17e-05	CcSEcCtD
Doxorubicin—Hyperhidrosis—Epirubicin—pancreatic cancer	4.04e-06	9.13e-05	CcSEcCtD
Doxorubicin—Anorexia—Epirubicin—pancreatic cancer	3.99e-06	9e-05	CcSEcCtD
Doxorubicin—Vomiting—Docetaxel—pancreatic cancer	3.94e-06	8.9e-05	CcSEcCtD
Doxorubicin—Rash—Docetaxel—pancreatic cancer	3.91e-06	8.83e-05	CcSEcCtD
Doxorubicin—Hypotension—Epirubicin—pancreatic cancer	3.91e-06	8.82e-05	CcSEcCtD
Doxorubicin—Dermatitis—Docetaxel—pancreatic cancer	3.91e-06	8.82e-05	CcSEcCtD
Doxorubicin—Headache—Docetaxel—pancreatic cancer	3.88e-06	8.77e-05	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.81e-06	8.6e-05	CcSEcCtD
Doxorubicin—Insomnia—Epirubicin—pancreatic cancer	3.78e-06	8.54e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Epirubicin—pancreatic cancer	3.75e-06	8.48e-05	CcSEcCtD
Doxorubicin—Dyspnoea—Epirubicin—pancreatic cancer	3.73e-06	8.42e-05	CcSEcCtD
Doxorubicin—Somnolence—Epirubicin—pancreatic cancer	3.72e-06	8.4e-05	CcSEcCtD
Doxorubicin—Nausea—Docetaxel—pancreatic cancer	3.68e-06	8.32e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Epirubicin—pancreatic cancer	3.68e-06	8.31e-05	CcSEcCtD
Doxorubicin—Decreased appetite—Epirubicin—pancreatic cancer	3.63e-06	8.21e-05	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.61e-06	8.15e-05	CcSEcCtD
Doxorubicin—Fatigue—Epirubicin—pancreatic cancer	3.61e-06	8.14e-05	CcSEcCtD
Doxorubicin—Constipation—Epirubicin—pancreatic cancer	3.58e-06	8.08e-05	CcSEcCtD
Doxorubicin—Pain—Epirubicin—pancreatic cancer	3.58e-06	8.08e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Epirubicin—pancreatic cancer	3.45e-06	7.78e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.42e-06	7.72e-05	CcSEcCtD
Doxorubicin—Urticaria—Epirubicin—pancreatic cancer	3.32e-06	7.5e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Epirubicin—pancreatic cancer	3.31e-06	7.47e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Epirubicin—pancreatic cancer	3.31e-06	7.47e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Epirubicin—pancreatic cancer	3.08e-06	6.96e-05	CcSEcCtD
Doxorubicin—Asthenia—Epirubicin—pancreatic cancer	3e-06	6.78e-05	CcSEcCtD
Doxorubicin—Pruritus—Epirubicin—pancreatic cancer	2.96e-06	6.68e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Epirubicin—pancreatic cancer	2.86e-06	6.46e-05	CcSEcCtD
Doxorubicin—Dizziness—Epirubicin—pancreatic cancer	2.77e-06	6.25e-05	CcSEcCtD
Doxorubicin—Vomiting—Epirubicin—pancreatic cancer	2.66e-06	6e-05	CcSEcCtD
Doxorubicin—Rash—Epirubicin—pancreatic cancer	2.64e-06	5.95e-05	CcSEcCtD
Doxorubicin—Dermatitis—Epirubicin—pancreatic cancer	2.63e-06	5.95e-05	CcSEcCtD
Doxorubicin—Headache—Epirubicin—pancreatic cancer	2.62e-06	5.92e-05	CcSEcCtD
Doxorubicin—Nausea—Epirubicin—pancreatic cancer	2.48e-06	5.61e-05	CcSEcCtD
Doxorubicin—ABCG2—Metabolism—GCG—pancreatic cancer	1.35e-06	6.74e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—APOE—pancreatic cancer	1.34e-06	6.7e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—pancreatic cancer	1.34e-06	6.7e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SLC2A2—pancreatic cancer	1.33e-06	6.65e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HRAS—pancreatic cancer	1.32e-06	6.57e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CD—pancreatic cancer	1.31e-06	6.56e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.31e-06	6.54e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMP—pancreatic cancer	1.3e-06	6.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CD—pancreatic cancer	1.3e-06	6.49e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SRC—pancreatic cancer	1.3e-06	6.47e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TERT—pancreatic cancer	1.29e-06	6.44e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NFKBIA—pancreatic cancer	1.29e-06	6.44e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—APOE—pancreatic cancer	1.29e-06	6.43e-05	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—AKT1—pancreatic cancer	1.28e-06	6.41e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.28e-06	6.4e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.28e-06	6.38e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NOTCH1—pancreatic cancer	1.28e-06	6.38e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.27e-06	6.35e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—STK11—pancreatic cancer	1.27e-06	6.34e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MYC—pancreatic cancer	1.26e-06	6.31e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—TGFB1—pancreatic cancer	1.26e-06	6.3e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CB—pancreatic cancer	1.26e-06	6.29e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.25e-06	6.26e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—STAT3—pancreatic cancer	1.25e-06	6.24e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CG—pancreatic cancer	1.25e-06	6.24e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—pancreatic cancer	1.25e-06	6.23e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NRAS—pancreatic cancer	1.25e-06	6.23e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PIK3CA—pancreatic cancer	1.25e-06	6.22e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—TYMS—pancreatic cancer	1.24e-06	6.19e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—pancreatic cancer	1.24e-06	6.17e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGF—pancreatic cancer	1.23e-06	6.17e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HIF1A—pancreatic cancer	1.23e-06	6.16e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TSC2—pancreatic cancer	1.23e-06	6.15e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMP—pancreatic cancer	1.23e-06	6.14e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.22e-06	6.08e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTEN—pancreatic cancer	1.21e-06	6.06e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CTNNB1—pancreatic cancer	1.21e-06	6.05e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CG—pancreatic cancer	1.21e-06	6.05e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—pancreatic cancer	1.2e-06	6.02e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APOE—pancreatic cancer	1.2e-06	6.01e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—TYMS—pancreatic cancer	1.2e-06	5.99e-05	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—AKT1—pancreatic cancer	1.2e-06	5.98e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.19e-06	5.96e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.18e-06	5.91e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTEN—pancreatic cancer	1.18e-06	5.9e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTEN—pancreatic cancer	1.17e-06	5.85e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PPARG—pancreatic cancer	1.17e-06	5.84e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KRAS—pancreatic cancer	1.17e-06	5.83e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—AKT1—pancreatic cancer	1.16e-06	5.8e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CG—pancreatic cancer	1.16e-06	5.8e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MYC—pancreatic cancer	1.16e-06	5.8e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFB1—pancreatic cancer	1.16e-06	5.79e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HRAS—pancreatic cancer	1.15e-06	5.76e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CB—pancreatic cancer	1.14e-06	5.72e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—pancreatic cancer	1.14e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—pancreatic cancer	1.13e-06	5.66e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CB—pancreatic cancer	1.13e-06	5.66e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PPARG—pancreatic cancer	1.12e-06	5.6e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOTCH1—pancreatic cancer	1.11e-06	5.55e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CD—pancreatic cancer	1.1e-06	5.48e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SRC—pancreatic cancer	1.09e-06	5.47e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—TYMS—pancreatic cancer	1.09e-06	5.45e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—pancreatic cancer	1.09e-06	5.44e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTEN—pancreatic cancer	1.09e-06	5.43e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.09e-06	5.43e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGF—pancreatic cancer	1.07e-06	5.37e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—pancreatic cancer	1.07e-06	5.36e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PIK3CA—pancreatic cancer	1.07e-06	5.36e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CD—pancreatic cancer	1.06e-06	5.32e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.06e-06	5.3e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—STAT3—pancreatic cancer	1.06e-06	5.27e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NRAS—pancreatic cancer	1.05e-06	5.26e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GLP1R—pancreatic cancer	1.05e-06	5.26e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.05e-06	5.25e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CASP3—pancreatic cancer	1.04e-06	5.2e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—DPYD—pancreatic cancer	1.03e-06	5.17e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CD44—pancreatic cancer	1.03e-06	5.15e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CD—pancreatic cancer	1.02e-06	5.1e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—AKT1—pancreatic cancer	1.02e-06	5.08e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCND1—pancreatic cancer	1.01e-06	5.06e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—APOE—pancreatic cancer	1.01e-06	5.04e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CTNNB1—pancreatic cancer	1e-06	5.02e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—pancreatic cancer	9.92e-07	4.96e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GLP1R—pancreatic cancer	9.91e-07	4.95e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTEN—pancreatic cancer	9.88e-07	4.94e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GCG—pancreatic cancer	9.88e-07	4.94e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PIK3CA—pancreatic cancer	9.85e-07	4.92e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—pancreatic cancer	9.84e-07	4.92e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SLC2A2—pancreatic cancer	9.82e-07	4.91e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MYC—pancreatic cancer	9.81e-07	4.9e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TGFB1—pancreatic cancer	9.78e-07	4.89e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTEN—pancreatic cancer	9.78e-07	4.89e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—DPYD—pancreatic cancer	9.75e-07	4.87e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—APOE—pancreatic cancer	9.75e-07	4.87e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—pancreatic cancer	9.59e-07	4.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CB—pancreatic cancer	9.56e-07	4.78e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CD—pancreatic cancer	9.55e-07	4.77e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.54e-07	4.77e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—STK11—pancreatic cancer	9.29e-07	4.64e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CB—pancreatic cancer	9.28e-07	4.64e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	9.25e-07	4.62e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.23e-07	4.61e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ARG2—pancreatic cancer	9.2e-07	4.6e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—pancreatic cancer	9.19e-07	4.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—pancreatic cancer	9.19e-07	4.59e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—pancreatic cancer	9.12e-07	4.56e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CG—pancreatic cancer	9.1e-07	4.55e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SRC—pancreatic cancer	9.07e-07	4.53e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—pancreatic cancer	9.06e-07	4.53e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CB—pancreatic cancer	8.89e-07	4.45e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	8.88e-07	4.44e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—APOE—pancreatic cancer	8.87e-07	4.43e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—pancreatic cancer	8.83e-07	4.42e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—pancreatic cancer	8.81e-07	4.4e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CG—pancreatic cancer	8.8e-07	4.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CASP3—pancreatic cancer	8.8e-07	4.4e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—pancreatic cancer	8.78e-07	4.39e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—AKT1—pancreatic cancer	8.76e-07	4.38e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—STAT3—pancreatic cancer	8.75e-07	4.37e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRAS—pancreatic cancer	8.73e-07	4.36e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCND1—pancreatic cancer	8.56e-07	4.28e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PIK3CA—pancreatic cancer	8.55e-07	4.27e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—pancreatic cancer	8.49e-07	4.24e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CTNNB1—pancreatic cancer	8.48e-07	4.24e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PIK3CA—pancreatic cancer	8.33e-07	4.16e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CB—pancreatic cancer	8.32e-07	4.16e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—pancreatic cancer	8.31e-07	4.15e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTEN—pancreatic cancer	8.26e-07	4.13e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PIK3CA—pancreatic cancer	8.25e-07	4.12e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—pancreatic cancer	8.25e-07	4.12e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MYC—pancreatic cancer	8.13e-07	4.06e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TGFB1—pancreatic cancer	8.11e-07	4.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT1—pancreatic cancer	8.05e-07	4.02e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMP—pancreatic cancer	8.04e-07	4.02e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTEN—pancreatic cancer	8.02e-07	4.01e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CG—pancreatic cancer	8e-07	4e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CD—pancreatic cancer	8e-07	4e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TYMS—pancreatic cancer	7.99e-07	3.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—pancreatic cancer	7.95e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CD—pancreatic cancer	7.73e-07	3.87e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—pancreatic cancer	7.72e-07	3.86e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—pancreatic cancer	7.7e-07	3.85e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTEN—pancreatic cancer	7.69e-07	3.84e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CA—pancreatic cancer	7.67e-07	3.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SRC—pancreatic cancer	7.66e-07	3.83e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CD44—pancreatic cancer	7.6e-07	3.8e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—pancreatic cancer	7.51e-07	3.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—pancreatic cancer	7.46e-07	3.73e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—STAT3—pancreatic cancer	7.39e-07	3.69e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CTNNB1—pancreatic cancer	7.38e-07	3.69e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRAS—pancreatic cancer	7.37e-07	3.68e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GCG—pancreatic cancer	7.29e-07	3.64e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTEN—pancreatic cancer	7.19e-07	3.59e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CD44—pancreatic cancer	7.17e-07	3.58e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CD—pancreatic cancer	7.04e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—AKT1—pancreatic cancer	6.99e-07	3.49e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CA—pancreatic cancer	6.97e-07	3.48e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CB—pancreatic cancer	6.97e-07	3.48e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—pancreatic cancer	6.91e-07	3.45e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CA—pancreatic cancer	6.9e-07	3.45e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GCG—pancreatic cancer	6.87e-07	3.43e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MYC—pancreatic cancer	6.87e-07	3.43e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—STK11—pancreatic cancer	6.85e-07	3.43e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TGFB1—pancreatic cancer	6.85e-07	3.42e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT1—pancreatic cancer	6.8e-07	3.4e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—AKT1—pancreatic cancer	6.74e-07	3.37e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CB—pancreatic cancer	6.74e-07	3.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—pancreatic cancer	6.72e-07	3.36e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—pancreatic cancer	6.68e-07	3.34e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—pancreatic cancer	6.68e-07	3.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SRC—pancreatic cancer	6.67e-07	3.33e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—APOE—pancreatic cancer	6.5e-07	3.25e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GLP1R—pancreatic cancer	6.48e-07	3.24e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—STK11—pancreatic cancer	6.46e-07	3.23e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—STAT3—pancreatic cancer	6.43e-07	3.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRAS—pancreatic cancer	6.42e-07	3.21e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—pancreatic cancer	6.38e-07	3.19e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—DPYD—pancreatic cancer	6.37e-07	3.19e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—pancreatic cancer	6.35e-07	3.17e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AKT1—pancreatic cancer	6.27e-07	3.13e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CB—pancreatic cancer	6.13e-07	3.06e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—pancreatic cancer	6.08e-07	3.04e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.05e-07	3.02e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTEN—pancreatic cancer	6.02e-07	3.01e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MYC—pancreatic cancer	5.98e-07	2.99e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFB1—pancreatic cancer	5.96e-07	2.98e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMS—pancreatic cancer	5.9e-07	2.95e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	5.87e-07	2.93e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—pancreatic cancer	5.85e-07	2.92e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CA—pancreatic cancer	5.83e-07	2.91e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTEN—pancreatic cancer	5.83e-07	2.91e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—AKT1—pancreatic cancer	5.7e-07	2.85e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—pancreatic cancer	5.66e-07	2.83e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CA—pancreatic cancer	5.66e-07	2.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—pancreatic cancer	5.64e-07	2.82e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT1—pancreatic cancer	5.64e-07	2.82e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMS—pancreatic cancer	5.56e-07	2.78e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—pancreatic cancer	5.52e-07	2.76e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CA—pancreatic cancer	5.42e-07	2.71e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—pancreatic cancer	5.39e-07	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTEN—pancreatic cancer	5.3e-07	2.65e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	5.16e-07	2.58e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CA—pancreatic cancer	5.07e-07	2.54e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOE—pancreatic cancer	4.79e-07	2.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT1—pancreatic cancer	4.76e-07	2.38e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—pancreatic cancer	4.69e-07	2.35e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CD44—pancreatic cancer	4.68e-07	2.34e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AKT1—pancreatic cancer	4.62e-07	2.31e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOE—pancreatic cancer	4.52e-07	2.26e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	4.5e-07	2.25e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GCG—pancreatic cancer	4.49e-07	2.24e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—pancreatic cancer	4.45e-07	2.23e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AKT1—pancreatic cancer	4.43e-07	2.21e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CG—pancreatic cancer	4.33e-07	2.16e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CA—pancreatic cancer	4.25e-07	2.12e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—STK11—pancreatic cancer	4.22e-07	2.11e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—pancreatic cancer	4.18e-07	2.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT1—pancreatic cancer	4.14e-07	2.07e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CA—pancreatic cancer	4.11e-07	2.05e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.08e-07	2.04e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.94e-07	1.97e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTEN—pancreatic cancer	3.88e-07	1.94e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CD—pancreatic cancer	3.8e-07	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CA—pancreatic cancer	3.74e-07	1.87e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.63e-07	1.82e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.58e-07	1.79e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKT1—pancreatic cancer	3.47e-07	1.73e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKT1—pancreatic cancer	3.36e-07	1.68e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.32e-07	1.66e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.29e-07	1.64e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.12e-07	1.56e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.1e-07	1.55e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKT1—pancreatic cancer	3.05e-07	1.53e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOE—pancreatic cancer	2.95e-07	1.48e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTEN—pancreatic cancer	2.87e-07	1.43e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	2.74e-07	1.37e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.7e-07	1.35e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.67e-07	1.33e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.57e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.34e-07	1.17e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKT1—pancreatic cancer	2.24e-07	1.12e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.04e-07	1.02e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.02e-07	1.01e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.02e-07	1.01e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.9e-07	9.52e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.77e-07	8.82e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKT1—pancreatic cancer	1.65e-07	8.25e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.56e-07	7.78e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.25e-07	6.22e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.02e-07	5.08e-06	CbGpPWpGaD
